An update from Cizzle Biotechnology Holdings PLC ( (GB:CIZ) ) is now available.
Cizzle Biotechnology Holdings PLC announced that its licensing partner, Cizzle Bio Inc, has signed its first laboratory contract in the Caribbean, triggering early royalty payments. This contract is part of an expanded licensing agreement covering the USA, Canada, and the Caribbean, aimed at rolling out the CIZ1B biomarker test for early-stage lung cancer detection. The expansion signifies progress in Cizzle Bio’s strategy to build a network of accredited laboratories, enhancing the test’s availability to clinicians and patients, and generating early revenues for Cizzle Biotechnology.
More about Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings PLC is a UK-based diagnostics developer specializing in early cancer detection tests. The company has developed the CIZ1B biomarker into a non-invasive, cost-effective blood test for early lung cancer detection. Cizzle has entered into commercial royalty-bearing arrangements to license its proprietary technology and collaborates with cancer care centers of excellence. The company was admitted to the London Stock Exchange in May 2021.
YTD Price Performance: -3.23%
Average Trading Volume: 675,204
Technical Sentiment Signal: Buy
Current Market Cap: £5.95M
For an in-depth examination of CIZ stock, go to TipRanks’ Stock Analysis page.